In the pipeline from Derek Lowe – Page 2
-
OpinionSlow march of the retrosynthesis robots
Software synthesis suggestions are hampered by biased and incomplete datasets
-
-
OpinionSurviving in the war of all against all
Cancers and bacteria develop resistance to drugs in remarkably similar ways
-
OpinionNavigating the literature torrent
It’s humanly impossible to filter and read everything worthwhile – let’s embrace assistance
-
OpinionBringing drug manufacturing back home
Pharmaceutical supply chains are international, complex and opaque. Is there a better way?
-
OpinionRegulators must follow their heads, not their hearts
The 2019 US approval of antibiotic Recarbrio seems not to have met the normally expected standards
-
OpinionWill a court overturn abortion drug’s approval?
Tangle between regulation and politics makes uncomfortable viewing from industry
-
OpinionMeeting the tigers of the lab
Practical teaching strikes a balance between removing hazards and learning to respect them
-
OpinionTurning negative results into positives
Publishing unsuccessful experiments is more important than ever as we try to train machines in chemistry
-
OpinionThe psychology of our future with AI
It’s time to accept that digitalisation is changing laboratory work, and embrace the opportunity
-
OpinionSetting drug development speed records
The pandemic treatment sprint was spectacular, but hard to match under less unusual circumstances
-
OpinionEmbracing oddities
When new chemistry looks like alchemy or witchcraft, it’s worth taking notice
-
OpinionNobel vision
Looking beyond the here-and-now let click chemistry open up a whole new world of possibility
-
OpinionDo science courses need hands-on labs to be effective?
The practical lab is where abstract theory connects to physical reality
-
OpinionWhy AlphaFold won’t revolutionise drug discovery
Protein structure prediction is a hard problem, but even harder ones remain
-
OpinionMay cause side effects
The dose makes the poison, but understanding unwanted drug interactions is complicated
-
OpinionAlzheimer’s, amyloid and abandoned antibodies
Biogen’s aducanumab is stumbling into obscurity. Where does that leave the amyloid hypothesis?
-
OpinionCatalogues of complexity
The tangled web of fine chemicals supply frequently throws up surprises
-
OpinionExit strategy
Overcoming a major setback showed Derek Lowe could make it through graduate school
-
OpinionA spanner in the works
Most drugs work by breaking or stopping something, rather than by making something faster or better